We also took advantage of the cross-reactivity of the anti-PD-L1 and anti-EGFR Nanofitins against the murine targets to demonstrate the in vivo anti-tumor activity of the bispecific molecule in a syngeneic immunocompetent model. This evidence concerns the gene EGFR and neoplasm.